Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: J Nucl Med. 2015 Oct 15;57(1):70–77. doi: 10.2967/jnumed.115.161646

FIGURE 2. Concordancy of gadolinium chelate enhancement and 18F-FDG PET avidity.

FIGURE 2

Bar graph showing (a) the outcome of the lesion-by-lesion analysis of 123 tumors in the subgroup of 36 patients and (b) the outcome of the patient-by-patient analysis in this subgroup (a): PET=MR 106/123, PET>MR 12/123, MR>PET 5/123; b): PET=MR 30/36, PET>MR 4/36, MR>PET 2/36).